Abstract: Provided are a filter cleaning apparatus and a filter cleaning system. The filter cleaning apparatus includes a shielding body, and at least one cleaning strip is arranged on an inner wall of the shielding body, a dust collection connector is arranged on the shielding body, one end of the dust collection connector is communicated with a dust collection apparatus, and the other end of the dust collection connector is communicated with a cavity in the shielding body. By arranging a dust collection connector on the filter cleaning apparatus, when the filter is cleaned, the dirt may be sucked into the dust collection apparatus in real time by the dust collection connector.

Abstract: The present disclosure provides novel compounds of Formula (I) below. Compounds of the disclosure act as STING modulators/agonists. The present disclosure further relates to methods of synthesis of compounds of Formula (I) and methods of using of compounds of Formula (I) for the prophylaxis or treatment of cancer and other STING-related diseases. The compounds have the structure represented by Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to methods of generating and expanding pitman embryonic stem cell derived mesenchymal-like stem/stromal cells. These hES-MSCs are characterized at least in part by the low level of expression of IL-6. These cells are useful for the prevention and treatment of T cell related autoimmune disease, especially multiple sclerosis, as well as for delivering agents across the bland-brain barrier and the blood-spinal cord barrier. Also provided is a method of selecting clinical grade hES-MSC and a method of modifying MSC to produced a MSC with specific biomarker profile. The modified MSC are useful for treatment of various diseases.

Abstract: The disclosure provided herein relates generally to mesenchymal-like stem cells “hES-T-MiSC” or “T-MSC” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblast in hES-T-MSC or T-MSC, T-MSC derived cells and cell lineages “T-MSC-DL” are also described. Disclosed also herein are solutions and pharmaceutical compositions comprising the T-MSC and/or T-MSC-DL, methods of making the T-MSC and T-MSC-DL, and methods of using the T-MSC and T-MSC-DL for treatment and prevention of diseases, specifically. T-MSC and T-MSC-DL are used as immunosuppressive agents to treat multiple sclerosis and autoimmune diseases.

Abstract: Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra?, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

Abstract: An array substrate having a substrate witha bonding region on one side, the bonding region having a plurality of bonding pads arranged in order, where at least one dummy pad is provided in a first position of the bonding pads. The at least one dummy pad is used for dividing the bonding region into a plurality of bonding sub-regions, where each bonding sub-region has a plurality of bonding pads. This disclosure further provides a display panel.

Abstract: An array substrate having a substrate witha bonding region on one side, the bonding region having a plurality of bonding pads arranged in order, where at least one dummy pad is provided in a first position of the bonding pads. The at least one dummy pad is used for dividing the bonding region into a plurality of bonding sub-regions, where each bonding sub-region has a plurality of bonding pads. This disclosure further provides a display panel.

Abstract: A system, a switch assembly and an associated method. The system includes a number of switch assemblies, each including a switch module, isolation circuits, a detection unit, and a drive unit. The switch module includes power switch devices connected in parallel. The switch modules are connected in series. The isolation circuits each are connected in series to a gate terminal of at least one corresponding power switch device of the power switch devices. Each isolation circuit includes a capacitor or a controllable switch. The detection unit detects faults in at least one of the power switch devices. The drive unit is coupled to the switch module via the isolation circuits for driving the power switch devices of the corresponding switch module, and when the fault is detected, the drive unit is for turning on the power switch devices parallel connected to the at least one of faulty power switch devices.

Abstract: Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra?, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

Abstract: The present invention relates to methods of generating and expanding hitman embryonic stem cell derived mesenchymal-like stem/stromal cells. These hES-MSCs are characterized at least in part by the low level of expression of IL-6. These cells are useful for the prevention and treatment of T cell related autoimmune disease, especially multiple sclerosis, as well as for delivering agents across the blood-brain barrier and the blood-spinal cord barrier. Also provided is a method of selecting clinical grade hES-MSC and a method of modifying MSC to produced a MSC with specific biomarker profile. The modified MSC are useful for treatment of various diseases.

Abstract: The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, L1, L2, m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

Abstract: The present disclosure relates to an integrated power semiconductor packaging apparatus and a power converter containing the integrated power semiconductor packaging apparatus. The integrated power semiconductor packaging apparatus comprises a plurality of power semiconductor devices and an electrically insulative substrate formed integrally. The electrically insulative substrate comprises a flat surface, at least one separation wall protruding from the flat surface and a flow channel inside the electrically insulative substrate. The at least one separation wall is configured to separate the flat surface into a plurality of flat areas, and each of the plurality of flat areas is configured to receive one of the plurality of power semiconductor devices. The flow channel is configured for allowing a coolant flowing through to remove heat from the plurality of power semiconductor devices.

Abstract: Disclosed are a device for preparing stem cell spheroids, a method for preparing stem cell spheroids and a method for preserving stem cells which relate to the technical field of preservation and transportation of stem cells. The device for preparing stem cell spheroids disclosed herein includes a substrate. The substrate is provided thereon with culture chambers, each of which has side walls and a bottom wall made of a material incompatible with stem cells. By culturing stem cells with this device, the stem cells may be made into spheroids and thus form stem cell spheroids. The device may be used as a means of preserving or transporting stem cells which makes it possible for stem cells to still have a higher viability and pluripotency even after a long time of preservation, storage and transportation under ambient temperature condition in the form of spheroids.

Abstract: The first method to cause a culture of human and other primate stem cells to directly and uniformly differentiate into a committed cell lineage is disclosed. Treatment of primate stem cells with a single protein trophoblast induction factor causes the cells to transform into human trophoblast cells, the precursor cells of the placenta. Several protein factors including bone morphogenic protein 4 (BMP4), BMP2, BMP7, and growth and differentiation factor 5 can serve as trophoblast-inducting factors.

Abstract: The present disclosure relates to a snubber circuit which comprises a static snubber unit, connected in parallel with the switch, for balancing a static voltage sharing across a switch when the switch is in a state of turn-on or turn-off; and a dynamic snubber unit for balance a dynamic voltage sharing across the switch when the switch is in a process of turn-on or turn-off, comprising a dynamic voltage sharing capacitor connected in parallel with the switch and having a relationship between a capacitance and a voltage of the dynamic voltage sharing capacitor; and a controller for controlling the capacitance of the dynamic voltage sharing capacitor to be in a predetermined working area of capacitance rising while the voltage across the switch is increasing. The present disclosure also relates to a power semiconductor device.

Abstract: A display substrate includes a rigid substrate, a flexible substrate, a pixel structure, and bonding terminals. The rigid substrate includes a portion corresponding to a display region of the display substrate. The flexible substrate is disposed on the rigid substrate, and includes a portion corresponding to the display region and a portion corresponding to a bonding region of the display substrate. The pixel structure is disposed in a region on the flexible substrate corresponding to the display region. The bonding terminals are disposed in a region one the flexible substrate corresponding to the bonding region. The portion of the flexible substrate corresponding to the bonding region is bendable.

Abstract: Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra?, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

Abstract: The disclosure provided herein relates generally to mesenchymal-like stem cells “hES-T-MiSC” or “T-MSC” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblast in hES-T-MSC or T-MSC, T-MSC derived cells and cell lineages “T-MSC-DL” are also described. Disclosed also herein are solutions and pharmaceutical compositions comprising the T-MSC and/or T-MSC-DL, methods of making the T-MSC and T-MSC-DL, and methods of using the T-MSC and T-MSC-DL for treatment and prevention of diseases, specifically. T-MSC and T-MSC-DL are used as immunosuppressive agents to treat multiple sclerosis and autoimmune diseases.

Abstract: In accordance with aspects of the present disclosure, an exemplary system includes a hollow probe having a lumen containing one or more excitation optical fiber(s) and one or more imaging optical fiber(s) where the probe is sized to access a person's body, a first light source optically coupled to the excitation fiber(s) and configured to emit light that excites fluorescence of NADH in breast tissue, a second light source optically coupled to the excitation fiber(s) and configured to emit light that excites fluorescence of FAD in tissue such as breast tissue, an image capturing device optically coupled to the imaging fiber(s), and a controller configured to control the first light source and the image capturing device to capture NADH fluorescence signals/intensities while the probe is within the person's body and control the second light source and the image capturing device to capture FAD fluorescence signals/intensities while the probe is within the person's body.

Abstract: An array substrate having a substrate witha bonding region on one side, the bonding region having a plurality of bonding pads arranged in order, where at least one dummy pad is provided in a first position of the bonding pads. The at least one dummy pad is used for dividing the bonding region into a plurality of bonding sub-regions, where each bonding sub-region has a plurality of bonding pads. This disclosure further provides a display panel.